MRI and 18FET-PET Predict Survival Benefit from Bevacizumab Plus Radiotherapy in Patients with Isocitrate Dehydrogenase Wild-type Glioblastoma: Results from the Randomized ARTE Trial.
Hans-Georg WirschingUlrich RoelckeJonathan WellerThomas HundsbergerAndreas F HottingerRoger von MoosFrancesca CaparrottiKatrin ConenLuca RemondaPatrick RothAdrian OchsenbeinGhazaleh TabatabaiMichael WellerPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
Large pretreatment contrast-enhancing tumor mass and higher ADCs identify patients who may experience a survival benefit from bevacizumab plus radiotherapy. Persistent 18FET-PET signal of no longer contrast-enhancing tumor after concomitant bevacizumab plus radiotherapy suggests pseudoresponse and predicts poor outcome.
Keyphrases
- wild type
- early stage
- locally advanced
- metastatic colorectal cancer
- contrast enhanced
- phase iii
- radiation induced
- radiation therapy
- computed tomography
- magnetic resonance
- positron emission tomography
- pet ct
- phase ii
- magnetic resonance imaging
- open label
- clinical trial
- double blind
- free survival
- rectal cancer
- pet imaging
- squamous cell carcinoma
- randomized controlled trial